j5create, a world leader in high tech computer accessories, and Intel®, the world's largest manufacturer of semiconductor chips, are working together to develop one of the worlds' first USB4™
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.32 by 121.88 percent. This is a 101.66 percent decrease over earnings of $4.21 per share